CTLA4 and neoplasm: A groundbreaking study demonstrated that blocking CTLA-4 with antibodies could induce a potent immune response and result in tumor shrinkage, thereby inaugurating the era of using antibodies to disinhibit immune cells for enhancing antitumor immune responses (92–94).Following clinical trials and efficacy evaluations, Ipilimumab, a CTLA-4 monoclonal antibody, blocks the binding of CTLA-4 to CD80/CD86 on APCs.